Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
← catalyst calendarNCT07431281 · readout in 1,093 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
2,130estimated
Sites
286
Countries
Australia, Austria, Belgium +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-03 | actual | When the study began enrolling |
| Primary completion | 2029-08-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-10-27 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Cancer
Interventions
- Drug: Sonesitatug vedotin — also filed as AZD0901
- Drug: Rilvegostomig — also filed as AZD2936
- Drug: Nivolumab
- Drug: Capecitabine
- Drug: 5-Fluorouracil
- Drug: Oxaliplatin
- Drug: Zolbetuximab
- Drug: Leucovorin
Primary outcomes
what the primary-completion date above is the date OFProgression Free Survival (PFS) (Cohort 1 and Cohort 2)
measured Up to approximately 5 years
Overall Survival (OS) (Cohort 1)
measured Up to approximately 5 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed